Too Fast, Too Much? Japan Cuts Prices By 6.7% As Annual Revisions Bite
Vyndaqel Slashed By 75%
The Japanese government will apply new drug reimbursement prices from 1 April, under which Pfizer’s Vyndaqel will be slashed by 75% and UCB's E Keppra by 26%. Nobelpharma and Santen will be also affected by the revision, which averages close to 7% across the board.
You may also be interested in...
Towa performed well during the financial year ended 31 March, delivering a ¥15.9bn profit, but questions remain about the impact of Japan’s NHI drug price revision and its acquisition of Sunsho Pharmaceuticals going forward.
While Japan enters annual drug price revisions with frequent regulation changes, several major corporate players in the country warn again that government policies mean that the country is at risk of “losing attractiveness.”
In the month ahead, Japanese firms are set to be hit with further price cuts to their generics, while Eagle Pharmaceuticals will throw off the restraints for its Pemfexy (pemetrexed) 505(b)(2) version of Eli Lilly’s Alimta.